Terms: = Thyroid cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
2 results:
1. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas.
Müssig K; Wehrmann T; Dittmann H; Wehrmann M; Ueberberg B; Schulz S; Bares R; Petersenn S
Clin Endocrinol (Oxf); 2012 Jul; 77(1):139-45. PubMed ID: 22248072
[TBL] [Abstract] [Full Text] [Related]
2. Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
[TBL] [Abstract] [Full Text] [Related]
